Association of hypertriglyceridemic waist phenotype with non-alcoholic fatty liver disease: a cross-sectional study in a Chinese population

Xuan, Yan; Ping, Guichen; Shen, Ying; Wang, Sujie; Gu, Xi; Tang, Dou; Wang, Xun; Zhu, Fengshuo; Lu, Leiqun; Chen, Ling

doi:10.1007/s42000-022-00374-x

Cited by 3 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our sample, HCC related to chronic infection with hepatitis B virus in the absence of MAFLD was associated with lower prevalence of hypertriglyceridemia than HCC of other etiologies [ 34 , 35 ]. Therefore, it is imperative to regularly monitor the blood lipid levels of individuals diagnosed with MAFLD and to intervene swiftly to resolve hypertriglyceridemia.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study

Yang,

Liu,

Wang

et al. 2024

Infect Agents Cancer

View full text Add to dashboard Cite

Aims This study compared the prevalences of metabolic syndrome and of cardiac or kidney comorbidities among patients with hepatocellular carcinoma (HCC) associated with metabolic dysfunction-related fatty liver disease (MAFLD), chronic infection with hepatitis B or C virus (HBV or HCV), or the combination of MAFLD and chronic HBV infection. Methods Medical records were retrospectively analyzed for patients with HCC who underwent hepatectomy between March 2013 and March 2023. Patients with HCC of different etiologies were compared in terms of their clinicodemographic characteristics and laboratory data before surgery. Results Of the 2422 patients, 1,822 (75.2%) were chronically infected with HBV without MAFLD and HCV, 415 (17.2%) had concurrent MAFLD and chronic HBV infection but no HCV infection, 121 (5.0%) had MAFLD without hepatitis virus infection, and 64 (2.6%) were chronically infected with HCV in the presence or absence of MAFLD and HBV infection. Compared to patients chronically infected with HBV without MAFLD and HCV, those with MAFLD but no hepatitis virus infection showed significantly lower prevalence of cirrhosis, ascites, portal hypertension, alpha-fetoprotein concentration ≥ 400 ng/mL, tumor size > 5 cm, multinodular tumors and microvascular invasion. Conversely, they showed significantly higher prevalence of metabolic syndrome, hypertension, type 2 diabetes, abdominal obesity, history of cardiovascular disease, T-wave alterations, hypertriglyceridemia and hyperuricemia, as well as higher risk of arteriosclerotic cardiovascular disease. Compared to patients with MAFLD but no hepatitis virus infection, those with concurrent MAFLD and chronic infection with HBV showed significantly higher prevalence of cirrhosis, ascites and portal hypertension, but significantly lower prevalence of hypertension and history of cardiovascular disease. Compared to patients with other etiologies, those chronically infected with HCV in the presence or absence of MAFLD and HBV infection, showed significantly higher prevalence of cirrhosis, portal hypertension, ascites, and esophagogastric varices. Conclusion Patients with HCC associated with MAFLD tend to have a background of less severe liver disease than those with HCC of other etiologies, but they may be more likely to suffer metabolic syndrome or comorbidities affecting the heart or kidneys.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study

Yang,

Liu,

Wang

et al. 2024

Infect Agents Cancer

View full text Add to dashboard Cite

show abstract

“…32,33 This study found that patients with CHB have a significantly lower risk of hypertriglyceridemia compared to patients with different etiologies, consistent with other studies. 34,35 Therefore, it is imperative to regularly monitor the blood lipid levels of individuals diagnosed with MAFLD and swiftly address any instances of hypertriglyceridemia.…”

Section: Discussionmentioning

confidence: 99%

Proportion of metabolic syndrome in hepatocellular carcinoma patients with different etiologies: a retrospective study

Yang,

Wang,

et al. 2023

Preprint

View full text Add to dashboard Cite

Aims This study aims to compare the proportion of metabolic syndrome (MetS) and cardiac or kidney comorbidities in patients with hepatectomy hepatocellular carcinoma (HCC) in the context of metabolic dysfunction-related fatty liver disease (MAFLD), chronic hepatitis B (CHB), concurrent CHB/MAFLD, or hepatitis C virus infection. Methods This retrospective study included patients with biopsy-proven HCC between March 2013 and March 2023. Cases were divided into MAFLD, CHB, CHB/MAFLD, and HCV groups. Preoperative demographic, clinical, and laboratory data were collected to compare the proportion of MetS and cardiac or kidney comorbidities. Results The proportions in the MAFLD, CHB, CHB/MAFLD, and HCV groups were 5.0% (n = 121), 75.2% (n = 1,822), 17.2% (n = 415), and 2.6% (n = 64), respectively. MAFLD patients had significantly lower proportions of cirrhosis, ascites, portal hypertension, alpha fetoprotein concentration ≥ 400 ng/mL, tumor size > 5cm, multinodular tumours, and microvascular invasion, but had significantly higher proportions of hypertension, type 2 diabetes, overweight, history of cardiovascular diseases, high arteriosclerotic cardiovascular disease risk, T-wave changes, hypertriglyceridemia, and hyperuricemia than CHB patients. CHB/MAFLD patients also had higher proportion of cirrhosis, ascites, and portal hypertension, but lower proportion of hypertension, overweight, and history of cardiovascular diseases compared to MAFLD patients (all p < 0.05). HCV group had higher proportion of cirrhosis, portal hypertension, ascites, and esophagogastric varices. Conclusion HCC patients in the setting of MAFLD have less severe liver disease but with higher proportion of MetS and cardiac or kidney comorbidities.

show abstract

“…While it is hard not to become involved in the treatment of this urgent health issue, it is all too easy to be overwhelmed by the ever accumulating data. In Hormones, as this issue demonstrates [5][6][7][8][9][10], we make a consistent effort to be at the forefront of dissemination of the most up-to-date information on obesity, prediabetes, diabetes, and MS. The Hellenic Endocrine Society, like other medical societies around the world, strives to be proactive and exercise maximum foresight, advocating for the prevention of obesity so as to * Constantine A. Stratakis castratakis@verizon.net; castratakis@elpen.gr effectively preclude its often hazardous consequences, these including MS, as well as to prevent, recognize, and treat another obesity-related disorder, non-alcoholic fatty liver disease (NAFLD) [5].…”

mentioning

confidence: 99%

Note by Hormones’ new editor: metabolic syndrome plus obesity and COVID-19, the two concurrent pandemics and the field of endocrinology

Stratakis

2022

Hormones

View full text Add to dashboard Cite

Association of hypertriglyceridemic waist phenotype with non-alcoholic fatty liver disease: a cross-sectional study in a Chinese population

Cited by 3 publications

References 40 publications

Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study

Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study

Proportion of metabolic syndrome in hepatocellular carcinoma patients with different etiologies: a retrospective study

Note by Hormones’ new editor: metabolic syndrome plus obesity and COVID-19, the two concurrent pandemics and the field of endocrinology

Contact Info

Product

Resources

About